Hims & Hers partners with Novo Nordisk to sell Wegovy and Ozempic, ending dispute Proactive uses images sourced from Shutterstock
Novo Nordisk (NYSE:NVO)and US telehealth company Hims & Hers (NYSE:HIMS) have announced a collaboration that will bring the Danish drugmaker’s weight-loss medications Wegovy and Ozempic to Hims & Hers’ platform, ending a recent legal dispute between the two companies.
The partnership marks a shift in strategy for Hims & Hers, which will now provide US customers access to a broad assortment of FDA-approved GLP-1 treatments, including semaglutide injections and tablets at various dosages.
The platform will continue to offer compounded semaglutide on a limited basis only when clinically necessary, while ceasing the promotion of compounded GLP-1s in marketing materials.
“The US weight loss landscape has evolved with more affordable, FDA-approved medications and flexible dosing options,” Hims & Hers co-founder and CEO Andrew Dudum said in a statement.
“We see tremendous growth opportunities with the expanding assortment of branded GLP-1 medications and are excited to have a great partner in Novo Nordisk.”
The agreement includes the introduction of Ozempic (0.5 mg, 1 mg, and 2 mg injections) and Wegovy (1.7 mg and 2.4 mg injections, as well as 1.5 mg, 4 mg, 9 mg, and 25 mg tablets) to the platform later this month.
Hims & Hers plans to educate customers on the full range of available treatments and support transitions to FDA-approved medications when clinically appropriate.
As part of the announcement, Novo Nordisk confirmed it is dismissing its lawsuit against Hims & Hers, which had been filed in February over a $49 compounded alternative to Wegovy, without prejudice.
Shares of Hims & Hers surged almost 38% on the news, while Novo Nordisk shares added 2.7%.